NasdaqGS:DXCMMedical Equipment
Assessing DexCom (DXCM) Valuation After Q1 2026 Beat Analyst Upgrades And Dexcom Flex Launch
DexCom (DXCM) has drawn fresh attention after multiple analysts shifted to “Outperform.” This coincides with robust Q1 2026 revenue of US$1.19b and the launch of Dexcom Flex for adults with Type 2 diabetes.
See our latest analysis for DexCom.
At a share price of US$72.10, DexCom has seen strong short term momentum, with a 7 day share price return of 10.77% and 30 day share price return of 17.10%. This is despite the 1 year total shareholder return being down 14.68% and the 3 year total...